liang yong

liang yong


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2025 in ImmunoTargets and Therapy
Verified
Journal Article
Open access
PDF file
TZTao Zhu
Tao Zhu
NCNiandie Cao
Niandie Cao
LTLi Tu
Li Tu
SOShiqi Ouyang
Shiqi Ouyang
ZWZengli Wang
Zengli Wang
XTXiaolong Tang
Xiaolong Tang
Background: Hepatocellular carcinoma (HCC) frequently develops resistance to sorafenib, a first-line treatment for advanced HCC. While PD-L1 contributes to immune evasion and direct tumor survival, its role in modulating sorafenib resistance via non-immunological pathways remains unclear. This study investigates the PD-L1/ITGB4 axis in regulating sorafenib sensitivity. Methods: Bioinformatics analysis of HCC datasets identified PD-L1/ITGB4 co-expression. Protein interaction was validated via co-immunoprecipitation (Co-IP). Functional impacts on FAK/AKT/mTOR signaling were assessed using kinase inhibitors and gene knockdown in HCC cell lines. Sorafenib sensitivity was evaluated in vitro and in xenograft models with mono- and combination therapies (PD-L1/ITGB4 inhibition ± sorafenib). Results: PD-L1 directly interacts with ITGB4 to activate the FAK/AKT/mTOR signaling pathway, independent of its immune-regulatory functions. This interaction critically mediates sorafenib resistance in HCC, as evidenced by significantly reduced drug sensitivity in PD-L1high/ITGB4high cells (p < 0.001). Crucially, genetic knockdown of either PD-L1 or ITGB4 effectively reversed this chemoresistance phenotype. In translational validation, combined pharmacological inhibition of the PD-L1/ITGB4 axis with sorafenib synergistically suppressed tumor progression in vivo, achieving > 60% greater volume reduction compared to monotherapies. Conclusion: The PD-L1/ITGB4 axis drives sorafenib resistance via FAK/AKT/mTOR hyperactivation. Dual targeting of PD-L1/ITGB4 enhances sorafenib efficacy, revealing a tumor-intrinsic mechanism and proposing a novel combinatorial strategy for HCC.

25 June 2026 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
WZWen Zhuang
Wen Zhuang
GXGuanyu Xiao
Guanyu Xiao
MZMengyao Zhang
Mengyao Zhang
JWJie Wang
Jie Wang
WTWenjing Tang
Wenjing Tang
LYliang yong
liang yong